On the Role of Delays to Diagnosis of Facioscapulohumeral Muscular Dystrophy

SHORT COMMUNICATION
Elan Schonfeld, Charulatha P. Nagar

 
International Journal of Biomedicine. 2022;12(3):474-475.
DOI: 10.21103/Article12(3)_ShC3
Originally published September 5, 2022

Abstract: 

Facioscapulohumeral muscular dystrophy (FSHD) is a rare genetic muscle disease that predominantly affects the facial, scapular, and humeral musculature. Scapular winging is the most common initial finding in patients with FSHD. FSHD can substantially impact a patient’s daily life, ranging from discomfort during work to athletic disadvantages. Another aspect of FSHD that is essential for obtaining successful patient outcomes is timely diagnosis, which can be challenging, possibly due to the heterogeneity of presenting features as well as the rarity of the condition. Some of the methods for increasing the ability to diagnose FSHD should include increased education regarding the disease, as well as other muscular dystrophies, specifically in underserved communities that may have less access to healthcare. Although there is currently no effective pharmacologic intervention for FSHD, recommendations of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine (2015) provide helpful guidance.

Keywords: 
facioscapulohumeral muscular dystrophy • scapular winging• diagnosis
References: 
  1. Tawil R, Kissel JT, Heatwole C, Pandya S, Gronseth G, Benatar M; Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology; Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine. Evidence-based guideline summary: Evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine. Neurology. 2015 Jul 28;85(4):357-64. doi: 10.1212/WNL.0000000000001783
  2. Statland JM, Tawil R. Facioscapulohumeral Muscular Dystrophy. Continuum (Minneap Minn). 2016 Dec;22(6, Muscle and Neuromuscular Junction Disorders):1916-1931. doi: 10.1212/CON.0000000000000399. 
  3. Preston MK, Tawil R, Wang LH. Facioscapulohumeral Muscular Dystrophy. 1999 Mar 8 [updated 2020 Feb 6]. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2022. PMID: 20301616.
  4. Martin RM, Fish DE. Scapular winging: anatomical review, diagnosis, and treatments. Curr Rev Musculoskelet Med. 2008 Mar;1(1):1-11. doi: 10.1007/s12178-007-9000-5.
  5. Snider L, Geng LN, Lemmers RJ, Kyba M, Ware CB, Nelson AM, Tawil R, Filippova GN, van der Maarel SM, Tapscott SJ, Miller DG. Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene. PLoS Genet. 2010 Oct 28;6(10):e1001181. doi: 10.1371/journal.pgen.1001181.
  6. van Deutekom JC, Wijmenga C, van Tienhoven EA, Gruter AM, Hewitt JE, Padberg GW, van Ommen GJ, Hofker MH, Frants RR. FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit. Hum Mol Genet. 1993 Dec;2(12):2037-42. doi: 10.1093/hmg/2.12.2037.
  7. Steel D, Main M, Manzur A, Muntoni F, Munot P. Clinical features of facioscapulohumeral muscular dystrophy 1 in childhood. Dev Med Child Neurol. 2019 Aug;61(8):964-971. doi: 10.1111/dmcn.14142. 

Download Article
Received June 4, 2022.
Accepted July 16, 2022.
©2022 International Medical Research and Development Corporation.